The role of erythropoietin and erythropoietin receptor expression in breast cancer

被引:0
|
作者
Budzik, M. P. [1 ]
Badowska-Kozakiewicz, A. M. [1 ]
机构
[1] Med Univ Warsaw, Dept Biophys & Human Physiol, Fac Hlth Sci, Warsaw, Poland
关键词
Breast neoplasms; Erythropoietin; Hypoxia; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; RECOMBINANT-HUMAN-ERYTHROPOIETIN; GENE-EXPRESSION; CELL CARCINOMA; EPO RECEPTOR; SURVIVAL; ANEMIA; GROWTH; STAT3; MIGRATION;
D O I
10.12892/ejgo4266.2019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Erythropoietin (EPO) plays a number of important functions in the body. Contrary to original beliefs, its activity is not limited to exerting effects on cells along the erythropoietic pathway. Newly published results continue to provide information on novel functions of the protein in other types of tissues, as well as on the important roles played by EPO in pathological processes. With no doubt, EPO has a significant impact on the biology of breast cancer cells by affecting cells' proliferation, apoptosis, resistance to chemotherapy, as well as expression of various types of receptors. EPO exerts its direct action on breast cancer stem-like cells by activation of specific signaling pathways responsible for protection of the tumor from chemotherapy and accelerating disease progression. EPO could inhibit chemotherapeutic drug-induced apoptosis and cytotoxicity. Its correlation with tissue hypoxia may play a significant role in the therapeutic resistance of hypoxic tumors. In recent years, the role of endogenous EPO in regulation of carcinogenesis was also noted. Exogenous EPO, in the form of rhEPO, had been introduced with best intention to treat patients with cancer-related anemia in the course of breast cancer. While it decreases the transfusion requirements and improves the quality of life of cancer patients, randomized trials have demonstrated that rhEPO administration is associated with shorter progression-free and overall survival. Observations allow also to say that EPO antagonizes treatment with the anti-HER2 antibody trastuzumab by activating EpoR/JAK2 downstream effectors, effectively bypassing HER2 signaling. Although increasing amount of information is available regarding the role of EPO and EpoR in breast cancer, elucidation of the activity and involvement of these proteins in complex processes occurring within the cancer cells requires extensive research. Every set of results being published answers some of the questions while instead raise new ones.
引用
收藏
页码:7 / 15
页数:9
相关论文
共 50 条
  • [41] Erythropoietin and erythropoietin receptor expression after experimental spinal cord injury encourages therapy by exogenous erythropoietin
    Grasso, G
    Sfacteria, A
    Passalacqua, M
    Morabito, A
    Buemi, M
    Macrì, B
    Brines, ML
    Tomasello, F
    NEUROSURGERY, 2005, 56 (04) : 821 - 826
  • [42] Erythropoietin and Soluble Erythropoietin Receptor: A Role for Maternal Vascular Adaptation to High-Altitude Pregnancy
    Wolfson, Gabriel H.
    Vargas, Enrique
    Browne, Vaughn A.
    Moore, Lorna G.
    Julian, Colleen G.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (01) : 242 - 250
  • [43] Expression of erythropoietin and its receptor in neuroblastomas
    Sartelet, Herve
    Fabre, Monique
    Castaing, Marine
    Bosq, Jacques
    Racu, Ivan
    Lagonotte, Emeryc
    Scott, Veronique
    Lecluse, Yann
    Barette, Stephane
    Michiels, Stefan
    Vassal, Gilles
    CANCER, 2007, 110 (05) : 1096 - 1106
  • [44] Erythropoietin receptor expression in normal and neoplastic choroid plexus
    Beschorner, R.
    Psaras, T.
    Meyermann, R.
    Bremer, J.
    Schmidt, T.
    Mittelbronn, M.
    Schittenhelm, J.
    CLINICAL NEUROPATHOLOGY, 2011, 30 (01) : 33 - 40
  • [45] Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway
    Fu, Ping
    Jiang, Xiaohong
    Arcasoy, Murat O.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 379 (03) : 696 - 701
  • [46] Expression of platelet-derived growth factor BB, erythropoietin and erythropoietin receptor in canine and feline osteosarcoma
    Meyer, F. R. L.
    Steinborn, R.
    Grausgruber, H.
    Wolfesberger, B.
    Walter, I.
    VETERINARY JOURNAL, 2015, 206 (01) : 67 - 74
  • [47] Expression of erythropoietin and its receptor increases in colonic neoplastic progression: The role of hypoxia in tumorigenesis
    Gombos, Zoltan
    Danihel, Ludovit
    Repiska, Vanda
    Acs, Geza
    Furth, Emma
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2011, 54 (02) : 273 - 278
  • [48] Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor
    Carolina Castillo Hernández
    Carlos Felipe Burgos
    Angela Hidalgo Gajardo
    Tiare Silva-Grecchi
    Javiera Gavilan
    Jorge Roberto Toledo
    Jorge Fuentealba
    Neural Regeneration Research, 2017, 12 (09) : 1381 - 1389
  • [49] Erythropoietin and its receptor in breast cancer: Putting together the pieces of the puzzle
    Mannello, Ferdinando
    Tonti, Gaetana A. M.
    ONCOLOGIST, 2008, 13 (07) : 761 - 768
  • [50] Landmark advances in the development of erythropoietin
    Fisher, James W.
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2010, 235 (12) : 1398 - 1411